MATIZ-SR

(Mebeverine 200mg SR Tablet)

Gastroenterology

MATIZ-SR

(Mebeverine 200mg SR Tablet)

Gastroenterology

Indications

Irritable bowel syndrome
Gastrointestinal tract spasm

How it works

Mebeverine is an antimuscarinic. It belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. This relieves painful muscle spasms of the gut, without affecting its normal motility. Mebeverine is used to relieve symptoms of irritable bowel syndrome and related intestinal disorders that are the result of spasms in the intestinal muscles. These include colicky abdominal pain and cramps, diarrhoea alternating with constipation and flatulence (wind).
Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, it has dual mode of action which normalizes the small bowel motility.

Indications

Irritable bowel syndrome
Gastrointestinal tract spasm

Dosage

Once/Twice daily therapy

Side Effects

Indigestion or heartburn
Constipation
Dizziness
Insomnia (difficulty sleeping)
anorexia (loss of appetite)
Headache
Tiredness
Slow heart beat
Rash and/or itchy skin

Contraindication

Meberverine
Paralytic ileus (occurrence of intestinal blockage)
Special precaution- Severe hepatic or renal impairment; cardiac disorders e.g. heart block; porphyria. May impair ability to drive or operate machinery.
Use in Pregnancy Category B2 Safe use in pregnancy has not been established with regards to possible adverse effects on foetal development. Therefore Mebeverine tablets are not recommended during the first trimester of pregnancy and otherwise risk-benefit must be considered in its use in pregnant women. Teratogenicity has not been demonstrated in teratology studies in rats and rabbits. Use in Lactation Mebeverine is secreted in breast milk (
Use in Pregnancy
Category B2 Safe use in pregnancy has not been established with regards to possible adverse effects on foetal development. Therefore Mebeverine tablets are not recommended during the first trimester of pregnancy and otherwise risk-benefit must be considered in its use in pregnant women. Teratogenicity has not been demonstrated in teratology studies in rats and rabbits
Use in Lactation Mebeverine is secreted in breast milk. Although problems have not been documented, as a general rule, Mebeverine tablets should not be given to a woman who is breastfeeding unless the anticipated benefits outweigh possible risks.

Technical information

Contact us

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Gastroenterology

Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
Uncategorized
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.